Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid

2025-12-25
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform

2025-12-23
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.

Best Momentum Stocks to Buy for Dec. 16

2025-12-16
PAAS, OMCL and MDB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Dec. 16, 2025.

3 Profitable Stocks That Fall Short

2025-12-11
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Is Omnicell (OMCL) Expanding OmniSphere Into Nursing Units Enough To Reinforce Its Moat?

2025-12-11
Earlier this month, Omnicell, Inc. launched Omnicell Titan XT in the United States, an enterprise automated dispensing system powered by its cloud-based, HITRUST-certified OmniSphere platform to unify medication management across pharmacy and nursing care areas. The Titan XT launch marks a meaningful extension of OmniSphere into nursing units, tightly linking automation, AI-enabled inventory intelligence, and embedded safety safeguards into a single enterprise medication management...

Is it Worth Retaining NEOG Stock in Your Portfolio for Now?

2025-12-10
Neogen leans on new product launches and 3M Food Safety integration to offset solvency strains and macro pressures.

Phibro Animal Health Stock Climbs 59.6% YTD: What's Driving It?

2025-12-10
PAHC's 59% YTD surge rides on strong Animal Health momentum, booming vaccines and global gains despite the rising competition.

ALGN Stock Rises on Thailand Launch of Invisalign With MAOB

2025-12-09
Align Technology's Thailand debut of Invisalign with MAOB lifts shares and expands its Class II treatment options for increasing patients.

Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now

2025-12-09
TNDM's global expansion and strategic integrations fuel growth potential, even as pump reliance and macro pressures weigh on performance.

Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations Transcript

2025-12-08
Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations December 8, 2025 7:01 PM ESTCompany...